3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
53
Neoplasms
23
Breast Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
13
Lung Neoplasms
12
Head and Neck Neoplasms
11
Neoplasm Metastasis
8
Carcinoma, Squamous Cell
7
Pancreatic Neoplasms
6
Colorectal Neoplasms
6
Stomach Neoplasms
5
Esophageal Squamous Cell Carcinoma
5
Prostatic Neoplasms
4
Multiple Myeloma
4
Esophageal Neoplasms
4
Lymphoma
3
Hematologic Neoplasms
3
Glioblastoma
3
Brain Neoplasms
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Non-small-cell Lung Cancer With Somatic EGFR Mutations
2
Melanoma
2
Glioma
2
Colonic Neoplasms
2
Adenocarcinoma of Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urethral Neoplasms
1
Interventions
Trastuzumab
1
Paclitaxel
1
Epirubicin
1
Cyclophosphamide
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Unilateral HER2 Positive Breast Cancer
×
Afatinib
×
Clear all
NCT01594177
2014-03-13
DAFNE
GBG Forschungs GmbH
Phase 2
Completed
65 enrolled